J. McKendrick

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

Jim Cassidy, Chris Twelves, Eric Van Cutsem et al. · Annals of Oncology · 2002 · 521 citations

Oncology, Gastrointestinal Oncology, Cancer Management +6

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study

Graham M. Mead, Matthew R. Sydes, Jan Walewski et al. · Annals of Oncology · 2002 · 335 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

Chris Twelves, Werner Scheithauer, J. McKendrick et al. · Annals of Oncology · 2011 · 198 citations · Full text

Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial

Jim Cassidy, Werner Scheithauer, J. McKendrick et al. · Journal of Clinical Oncology · 2004 · 74 citations

Surgical Oncology, Cancer Management, Pharmacotherapy +17

A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer

Samuel Y. Ngan, Michael Michael, John Mackay et al. · British Journal of Cancer · 2004 · 70 citations · Full text